WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005009334) REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/009334    International Application No.:    PCT/US2004/011229
Publication Date: 03.02.2005 International Filing Date: 09.04.2004
IPC:
A61K 31/52 (2006.01), A61K 45/06 (2006.01), C07D 473/34 (2006.01)
Applicants: GENERAL ATOMICS [US/US]; 3550 General Atomics Court, P.O. Box 85608, San Diego, CA 92186-5608 (US) (For All Designated States Except US).
YUAN, Chong-Sheng [US/US]; (US) (For US Only)
Inventors: YUAN, Chong-Sheng; (US)
Agent: CHEN, Peng; Morrison & Foerster LLP, 3811 Valley Centre Drive, Suite 500, San Diego, CA 92130-2332 (US)
Priority Data:
10/410,879 09.04.2003 US
Title (EN) REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF
(FR) INHIBITEURS REVERSIBLES DE S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE ET LEURS UTILISATIONS
Abstract: front page image
(EN)The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes.
(FR)L'invention concerne des compositions et des procédés permettant d'inhiber de manière réversible S-adénosyl-L-homocystéine (SAH) hydrolase. Les composés selon l'invention peuvent être utilisés combinés avec un agent infectieux viral antihémorragique, un immunosuppresseur, un agent abaissant l'homocystéine, ou un agent anti-néoplasme. Les compositions et les procédés selon l'invention peuvent servir dans la prévention et le traitement d'infection virale hémorragique, de maladies auto-immunes, de rejet d'autogreffe, de néoplasme, d'hyperhomocystéineuria. De maladie cardiovasculaire, d'accident cérébrovasculaire, de maladie d'Alzheimer ou des diabètes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)